Table 1—

Baseline characteristics according to the presence of metabolic syndrome and associations between the different components of the metabolic syndrome: the 3C Study, France, 1999–2004

Total cohortMetabolic syndromeNo metabolic syndromePComponents of the metabolic syndrome
High blood pressureHigh waist circumferenceHigh triglyceridesLow HDL cholesterolHigh glycemia
n7,0871,1215,9666,0642,0491,247741816
Age (years)73.4 ± 4.973.8 ± 4.873.4 ± 4.90.0573.7 ± 4.974.0 ± 4.973.3 ± 4.973.6 ± 4.973.2 ± 4.7
Men (%)39.041.638.50.0540.832.345.935.439.0
Education level (no or primary)23.629.122.6<0.000124.428.825.929.923.6
ApoE ε4*20.421.020.30.6020.319.620.423.520.4
High blood pressure85.698.283.2<0.0001NA91.690.088.395.2
High waist circumference28.978.519.6<0.000131.0NA44.250.450.2
High triglycerides§17.666.48.4<0.000118.526.9NA50.532.0
Low HDL cholesterol10.547.63.5<0.000110.818.330.2NA22.8
High glycemia11.547.64.7<0.000112.920.020.925.0NA
Impaired fasting glucose without diabetes**3.915.31.8<0.00014.36.96.17.034.2
Diabetes††7.632.32.9<0.00018.613.114.818.065.8
  • Data are means ± SD or percent. Metabolic syndrome was defined by the NCEP ATP III criteria.

  • * ApoE ε4: presence of at least one allele ε4 in apoE genotype.

  • Systolic blood pressure >130 mmHg or diastolic blood pressure >85 mmHg or medication.

  • Waist circumference >88 cm in women or >102 cm in men.

  • § Triglycerides ≥150 mg/dl.

  • HDL cholesterol <50 mg/dl in women or <40 mg/dl in men.

  • Fasting glycemia ≥110 mg/dl or nonfasting glycemia ≥200 mg/dl or antidiabetes medication.

  • ** Impaired fasting glucose ≥110 mg/dl without diabetes.

  • †† Diabetes: fasting glycemia ≥126 mg/dl or nonfasting glycemia ≥200 mg/dl or antidiabetes medication. P value: Student and Pearson χ2 tests used for continuous and categorical variables, respectively, to compare baseline characteristics between subjects with metabolic syndrome and those without. NA, nonapplicable.